SCHEMBL6293579

SCHEMBL6293579

COc1ccc(C(=O)Nc2ccc3c(c2)CN(C(C)C)CC3)cc1C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 5/20 0.53
MAPT P10636 2/20 0.49
CYP3A4 P08684 1/20 0.49
TP53 P04637 1/20 0.49
THRB P10828 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.48
NPC1 O15118 1/20 0.48
BRAF P15056 5/20 0.47
RAF1 P04049 1/20 0.46
ABCB1 P08183 1/20 0.45
ABCG2 Q9UNQ0 1/20 0.45
TMPRSS2 O15393 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6299431 0.93 ROCK2 (0.51) ROCK2MAPTCYP3A4TP53THRB
SCHEMBL6293655 0.88 ROCK2 (0.61) ROCK2MAPTCYP3A4TP53THRB
SCHEMBL6294900 0.85 ABCB1 (0.54) ROCK2MAPTCYP3A4TP53THRB
SCHEMBL6293557 0.85 NPC1 (0.50) ROCK2MAPTCYP3A4TP53THRB
SCHEMBL7801373 0.85 ROCK2 (0.55) ROCK2MAPTCYP3A4TP53THRB
SCHEMBL6295051 0.83 ABCB1 (0.57) ROCK2MAPTCYP3A4TP53THRB
SCHEMBL6299432 0.83 ABCB1 (0.57) ROCK2MAPTCYP3A4TP53THRB
SCHEMBL6298344 0.83 ROCK2 (0.56) ROCK2MAPTCYP3A4TP53THRB
Hydrochloric Acid SCHEMBL8103004 0.81 MAPT (0.49) ROCK2MAPTCYP3A4TP53SMN1; SMN2
Hydrochloric Acid SCHEMBL6295081 0.80 ROCK2 (0.59) ROCK2MAPTCYP3A4TP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 US claimed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 US claimed
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 US disclosed
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2004-10-21 US disclosed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 US disclosed
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A ROCK2 2314/4885MAPT 353/4885CYP3A4 168/4885
US-20010016657-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A ROCK2 2314/4885MAPT 353/4885CYP3A4 168/4885
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders PNMT, SLC6A2, GABBR1 ROCK2 4693/4885MAPT 1087/4885CYP3A4 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.